Case Series: The Effectiveness of Fatty Acids from Pracaxi Oil in a Topical Silicone Base for Scar and Wound Therapy by Daniel Banov et al.
ORIGINAL RESEARCH
Case Series: The Effectiveness of Fatty Acids
from Pracaxi Oil in a Topical Silicone Base
for Scar and Wound Therapy
Daniel Banov • Fabiana Banov • August S. Bassani
To view enhanced content go to www.dermtherapy-open.com
Received: August 27, 2014 / Published online: November 20, 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Wounding affects the integrity
of the skin and can ultimately result in skin
scarring. Current therapeutic goals of wound
treatment focus on the reduction of scar
formation and severity. However, scar
formation itself varies not only between
individuals based on factors such as ethnicity,
but also within an individual based on the
location of the wound. Therefore, the
preparation of customized treatments for
individual patients represents an important
therapeutic goal in the fields of dermatology
and wound healing. The objective of this study
was to evaluate the usefulness of fatty acids
found in pracaxi oil in a compounded topical
anhydrous silicone base for wound and scar
therapy.
Methods: Initially, 21 patients with various
surgical, traumatic, or burn wounds and scars
were enrolled into this case series. Patients
applied a compounded topical anhydrous
silicone base containing pracaxi oil with or
without additional active ingredients, including
pentoxifylline, caffeine, tranilast, and
mupirocin. Wound/scar photographs taken
before and after application of the
compounded pracaxi oil topical formulation
(with/without additional ingredients) were
reviewed and adjudicated by a blinded
dermatology reviewer. Improvements in
wound size, coloration, and overall appearance
before and after treatment were determined.
Patient satisfaction was assessed after
application of compounded topical
formulation using a self-report questionnaire
distributed at the time of dispensing.
Results: A total of seven patients were
considered available for analysis and were
included in the study. In all seven cases,
patients reported improvement in scar and
wound attributes, including scar and wound
size, severity, color, and pain associated with
the scar or wound after application of the
compounded medicine. On average, patients
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rated their satisfaction with treatment highly,
with a mean score of 10 on a rating scale of
1–10. Retrospective review of wound/scar
photographs demonstrated clinically relevant
improvements in wound attributes as assessed
by a dermatologist. Six of the seven wounds
examined were considered ‘‘much improved’’
from baseline.
Conclusions: Application of a compounded
anhydrous silicone base containing pracaxi oil
alone or in combination with other active
substances led to considerable improvements
in wound healing and scar attributes and is a
potentially useful option in the treatment of
surgical, traumatic, or burn wounds and scars.
Keywords: Fatty acids; Pracaxi oil; Scarring;
Wound healing
INTRODUCTION
All wounds affect the integrity of the skin and
can result in the imperfect, although normal,
end point of tissue repair, namely, skin scarring.
Phenotypically, scars can range from a fine line
to a variety of abnormal scars, including
hypertrophic and keloid scars. While skin
scarring is often considered trivial, it can be
aesthetically unpleasant and disfiguring, and
can cause distress and anxiety to the patient [1].
Scarring can also have physical consequences
including tenderness, itching, and pain, which
can be functionally disabling and can
contribute to a diminished quality of life
(reviewed in [2]).
Currently, the therapeutic goal of wound
and scar treatment is to reduce the severity of
scars as much as possible. However, this is
difficult as there is considerable qualitative and
quantitative variability in skin scarring between
individuals. A genetic predisposition to
abnormal skin scarring has been demonstrated
in certain ethnic populations [3]. In addition,
scars can vary within an individual, as scars are
normally more severe in certain locations of the
body, including those with frequent
movement. Consequently, a personalized
approach to the clinical treatment of wounds
and scars based on both the wound or scar
attributes and the patient allows for improved
treatment [2–4]. Compounding, the preparation
of customized medications to meet the specific
needs of individual patients, allows patients the
benefit of a personalized treatment and
represents an invaluable therapeutic
alternative in dermatology [5]. Compounded
medications may be personalized to include
special combinations of active substances in
particular concentrations, as well as to include
specific raw materials or provide certain
organoleptic characteristics adjusted to the
patient’s skin type and disorder [6]. The use of
compounded topical formulations has already
proven successful in wound care [7, 8].
Pracaxi oil, derived from the seeds of the
Pentaclethra macroloba tree indigenous to the
Amazon, has several medicinal applications
including the treatment of ulcers, stretch
marks, bacterial infections, and snake bites [9,
10]. Pracaxi oil contains high amounts of oleic,
linoleic, and behenic fatty acids, which are
frequently utilized in the cosmetic industry [9]
and have been shown to enhance wound
closure and improve healing in several wound
models [11, 12]. Fatty acids are integral to the
formation and maintenance of cell membranes
within the stratum corneum, the layer of the
skin that provides a barrier to the environment
and regulates permeability [13]. In addition,
fatty acids have lubricant, emollient, and anti-
inflammatory properties, which help to restore
the natural oils of the skin and protect the skin
from environmental damage [14].
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Fatty acids have also been shown to enhance
topical drug delivery of many active
pharmaceutical ingredients, including water-
and oil-soluble products [15]. However, topical
application of fatty acids, especially unsaturated
fatty acids such as oleic acid, can irritate the
skin [16]. Pracaxi oil contains high levels of
behenic acid and oleic acid, and has been used
topically by native Amazonians to treat a
variety of diseases [17].
In this case series, the healing properties of
pracaxi oil in a compounded topical anhydrous
silicone base were examined in patients with
surgical, traumatic, moisture-associated, or
burn-related wounds and scars. We
hypothesized that incorporation of pracaxi oil
in a compounded anhydrous silicone base
would have a positive effect on wound healing
and scar formation through the beneficial
effects of the fatty acids contained within
pracaxi oil. Furthermore, the composition of
this base allowed for the addition of active
substances at different concentrations to
produce a personalized treatment. This also
allowed for the evaluation of the effectiveness
of pracaxi oil in combination with other
compounded active ingredients in improving




This case series was conducted between March
2013 and March 2014. Twenty-one patients
with surgical, traumatic, or burn wounds and
scars who used compounded topical anhydrous
silicone base containing pracaxi oil were
enrolled in this case series. All patients were
dispensed medicine at compounding sites
within the United States, with the exception
of one patient who was dispensed medicine at a
site in Portugal, and all were enrolled during the
course of treatment. In August 2014, data from
seven patients were adjudicated by an
independent dermatology reviewer. All
procedures followed were in accordance with
an internal committee on human
experimentation and with the Helsinki
Declaration of 1975, as revised in 2000 and
2008. Informed consent was obtained from all
patients (or their legal guardians) for being
included in the study and for publication of
the photographs.
Compounded Topical Base Containing
Pracaxi Oil: Composition and Application
The topical anhydrous silicone base used in this
study was a proprietary combination of
ingredients, which included
cyclopentasiloxane, polysilicone-11, PEG-16
macadamia glycerides, dimethicone, C30-45
alkyl cetearyl dimethicone crosspolymer,
Pentaclethra macroloba seed oil, Oenocarpus
bataua pulp oil, phosphatidylcholine,
tocopheryl acetate, and butylated
hydroxytoluene.
The topical anhydrous silicone base
containing pracaxi oil was applied alone, or
was compounded with one or more additional
medications tailored to the specific needs of
each patient. These additional medications
included 1% pentoxifylline, 1% caffeine, 1%
tranilast, or 2% mupirocin. Patients were
advised to apply the compounded topical
medication to new or existing scar or wound
areas by lightly massaging the compound into
and around the scar or wound. The
recommended application frequency was two
to four times daily based on the attributes of the
scar or wound, including size and severity, at
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baseline (i.e., before application of the topical
medication).
Assessment Using a Patient Self-report
Questionnaire
A patient self-report questionnaire was
developed and distributed to patients or
guardians at the time of dispensing the topical
medication. The questionnaire gathered
information on patient demographics, prior
and current wound or scar therapy, duration
of use of compounded topical anhydrous
silicone base containing pracaxi oil, and
whether the base was used alone or was
compounded with additional active
pharmaceuticals.
Patients rated their overall satisfaction with
the compounded topical medication on a scale
of 0 (minimum) to 10 (maximum) once at the
completion of treatment. Patients were
instructed to return the results of the
questionnaire after they had stopped using the
topical medication. Acceptable methods of
reporting the questionnaire results included
the following: return of a written copy of the
questionnaire to the pharmacist or investigator,
verbal answers to the questionnaire via a
telephone conversation with the pharmacist,
emails to the pharmacist, or video recordings of
the patient’s experience made available to the
pharmacist and investigator.
Assessment of Wound or Scar
Improvement over Time
To assess any clinically relevant improvements
in wound and scar attributes, photographs of
the scar or wound were taken by the patient or
guardian at baseline (i.e. prior to application of
the topical medication), and at specific time
points throughout and at completion of the
application period. Patient photographs were
processed using CorelDraw X5 (Corel
Corporation, Ottawa, Ontario, Canada) and
were reviewed and adjudicated by an
independent, blinded dermatologist.
Improvement in the scar or wound attributes
over time, including wound size, coloration and
overall appearance, were graded by the reviewer
using a physician’s global impression of
improvement scale of ‘‘much worse’’, ‘‘worse’’,
‘‘neutral’’, ‘‘improved’’, or ‘‘much improved’’.
RESULTS
Of the 21 patients enrolled in the case series, 7
completed the patient self-report questionnaire
and had clinical photographs for consideration
and review. The seven patients ranged in age
from 5 months to 72 years and had a variety of
wound types including surgical, traumatic,
burn, and moisture-associated wounds
(Table 1). The mean duration of application of
the compounded topical anhydrous base
containing pracaxi oil was 11 days [standard
deviation (SD) 6.11 days], ranging from 48 h to
3 weeks based on the size and severity of the
wound or scar.
Overall patient satisfaction with the use of
compounded topical anhydrous silicone base
containing pracaxi oil alone, or in combination
with other active substances, was high. Using
the patient self-report questionnaire to rate
satisfaction on a scale from 1 to 10, patients
reported a mean score of 10 (SD 1.15) following
application. In addition, no adverse effects were
reported to the pharmacist or investigator
during the course of the study.
Retrospective dermatological review of
patients’ wounds and scars also revealed
clinical improvement in the wound or scar
attributes over time following application of the
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compounded topical anhydrous silicone base
containing pracaxi oil with or without active
pharmaceutical substances. Of the seven patient
photographs reviewed, six wounds/scars were
considered to be ‘‘much improved’’ when
compared with their respective baseline images
and one wound/scar, which was treated with
topical base containing pracaxi oil alone, was
considered to be ‘‘improved’’ compared with
baseline. No wounds or scars were considered to
be ‘‘neutral’’, ‘‘worse’’, or ‘‘much worse’’ after
application compared with baseline (Fig. 1). The
individual compounded topical medications
applied and the outcomes of each patient are
described in detail in the following sections.
Case 1: New Surgical Ankle Scar
A 50-year-old female diagnosed with
osteochondritis dissecans of the right talus













Case 1 50 F Surgical New Ankle Anhydrous silicone base with pracaxi oil 14
Case 2 57 F Surgical Existing Ankle Anhydrous silicone base with pracaxi oil 7
Case 3 72 M Burn New Head
and
neck
Anhydrous silicone base with pracaxi oil 14




Anhydrous silicone base with pracaxi oil 2
Case 5 0.42 F Burn New Face Anhydrous silicone base with pracaxi oil 8
Case 6 22 F Traumatic
and
surgical
Existing Face Anhydrous silicone base with pracaxi oil
containing 1% pentoxifylline (antiﬁbrogenic),
1% caffeine (promotes circulation), and 1%
tranilast (collagen synthesis inhibitor)
21
Case 7 40 F Traumatic New Bilateral
elbows
Anhydrous silicone base with pracaxi oil
containing 2% mupirocin (antibacterial)
11
Characteristics, wound/scar attributes, and application regimen
F female, M male
Fig. 1 Photographs of wounds and scars were taken at
baseline (prior to application of compounded topical
anhydrous silicone base containing pracaxi oil) and at
the end of the application period. Photographs were
retrospectively reviewed by an independent dermatological
reviewer who graded the changes in wounds/scars from
baseline to the end of the application period using a scale
of ‘‘much worse’’, ‘‘worse’’, ‘‘neutral’’, ‘‘improved’’, and ‘‘much
improved’’
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underwent osteochondral allograft surgery for
the second time. The patient was advised to
wait 10 days after removal of the stitches before
applying any topical medication. After 10 days,
the patient initiated application of the topical
anhydrous silicone base containing pracaxi oil,
with no additional active substances, twice daily
(Fig. 2a). Following 2 weeks of application, the
thickness of the surgical scar was visibly reduced
(Fig. 2b), and the wound was graded as ‘‘much
improved’’. The patient reported drastic
improvement in the feel and size of the scar,
and noted less irritation in the area.
Case 2: Pre-existing Surgical Ankle Scar
A 57-year-old female with type I diabetes
underwent 3 reconstructive surgeries following
a fractured ankle. These surgeries resulted in 3
ankle scars, including one hypertrophic scar.
Prior to this study, the patient had applied
several different products to the scars, but still
experienced itching associated with the
hypertrophic scar and was generally not
satisfied with the aesthetics of the scar
(Fig. 3a). One year after her last surgery, the
patient began application of compounded
topical anhydrous silicone base containing
pracaxi oil, without additional active
substances, twice daily to the hypertrophic
scar. Following 1 week of application, the
patient reported that the overall severity as
well as the thickness and coloration of the scar
were considerably improved (Fig. 3b), and the
scar was graded as ‘‘much improved’’.
Case 3: New Radiation Burn
A 72-year-old male underwent a surgical
removal procedure and 33 sessions of radiation
therapy on the right side of the head and neck
to treat acinic cell carcinoma. The patient
experienced radiation burns at the site of
treatment with extremely sensitive, dry, and
scaly skin resulting in extreme pain and
discomfort (Fig. 4a). Topical compounded
anhydrous silicone base containing pracaxi oil
without additional active ingredients was
applied to the radiation burn 4 times daily, or
as needed to relieve discomfort. Following
4 days of application, the patient
acknowledged significant healing and tissue
regrowth. By day 10, the radiation burn was
almost completely healed and pain free, and on
day 14, the skin was smooth, soft, and pink and
the patient reported that he was pain free
Fig. 2 Surgical scar 10 days after osteochondral allograft
surgery a before and b 2 weeks after application of
compounded base containing pracaxi oil
Fig. 3 A hypertrophic surgical scar following reconstruc-
tive surgery of the ankle a before and b 1 week after
application of compounded base containing pracaxi oil
Fig. 4 Radiation burn to the right side of the head and
neck a before and b 2 weeks after application of
compounded base containing pracaxi oil
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(Fig. 4b). The burn was considered ‘‘much
improved’’ by an independent dermatology
reviewer.
Case 4: Pediatric Diaper Rash
The guardians of a 15-month-old female
suffering from diaper rash, a moisture-
associated skin condition, had previously
treated the patient with several over-the-
counter topical products without success. The
condition worsened with time, resulting in
increased pain and discomfort for the child
(Fig. 5a). Application of compounded topical
anhydrous silicone base containing pracaxi oil
(without additional active ingredients) was
recommended two to four times daily at
diaper change. After 48 h of application, the
diaper rash had improved (Fig. 5b) and the
toddler no longer appeared to experience pain
or discomfort. The rash was considered
‘‘improved’’ from baseline by an independent
dermatology reviewer.
Case 5: Pediatric Facial Burn
A 5-month-old female was severely scalded with
liquid on the face, resulting in a major second
degree burn (Fig. 6a). Following the incident,
compounded topical anhydrous silicone base
containing pracaxi oil without additional active
ingredients was applied twice daily to the burn,
with sterile bacitracin ointment to prevent
infection. After 8 days of application, the
infant’s facial wound healed completely with
no evidence of scarring (Fig. 6b). The burn was
considered ‘‘much improved’’ from baseline
after the application of compounded
anhydrous silicone base containing pracaxi oil.
Case 6: Pre-existing Facial Scars
A 22-year-old female was left severely scarred on
the face following a car accident. The patient
had undergone six plastic surgery procedures
and had previously used several treatments to
lessen scar formation. However, she was still
unsatisfied with her facial scars and overall
complexion (Fig. 7a). Four years after the
accident occurred, the patient began
application of a medicine containing 1%
pentoxifylline (a collagen and wound
contraction inhibitor), 1% caffeine (to increase
blood flow to the area), and 1% tranilast
Fig. 5 Diaper rash on a 15-month-old child a before and
b 48 h after application of compounded base containing
pracaxi oil
Fig. 6 A second degree facial burn on the face of a
5-month-old infant a before and b 8 days after application
of compounded base containing pracaxi oil
Fig. 7 Pre-existing facial scars following traumatic injury
and plastic surgery a before and b 3 weeks after application
of a compounded medicine comprising 1% pentoxifylline,
1% caffeine, and 1% tranilast in a topical anhydrous
silicone base containing pracaxi oil
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(a collagen synthesis inhibitor) in topical
compounded anhydrous silicone base
containing pracaxi oil.
The compounded medicine was applied
twice daily to the facial scars. After 3 weeks of
application, there was an overall improvement
in the severity of the scars and the patient
reported that the skin around the scar was softer
and that the redness of the scar had decreased
(Fig. 7b). The scars were considered ‘‘much
improved’’ from baseline following application
of the compounded medicine.
Case 7: Multiple Elbow Wounds
A 40-year-old female fell on both elbows and was
painfully injured as a result of repeated impact
with the ground during a fitness competition.
Multiple layers of skin were scraped off and the
patient presented with open wounds on the right
and left elbows (Fig. 8a, b).
The patient was instructed to apply a
compounded medication containing 2%
mupirocin in compounded topical anhydrous
silicone base containing pracaxi oil three times
a day. Mupirocin 2% was added to the
compounded base to prevent bacterial
contamination of the wounds. After 11 days of
application, the wounds on both the right and
left elbows were completely closed and the
patient reported fast improvement in the use
of her elbows (Fig. 8c, d). The wounds were
considered ‘‘much improved’’ from baseline
following application of the compounded
medicine.
DISCUSSION
The ability to create personalized treatments
for the management of wounds and scarring is
a particularly attractive premise, as it enables
therapies to be tailored to the management of
wounds and scars of different sizes and
etiologies, and at different locations.
Compounding of medications allows for the
preparation of specialized treatments
containing specific active ingredients at
different concentrations and provides
personalized therapy for the patient. This
case series characterized the effects of pracaxi
oil in a compounded topical anhydrous
silicone base on wounds and scars in seven
patients.
A recent gas chromatography analysis of
pracaxi oil demonstrated that the oil is
comprised of approximately 53% oleic acid,
26% linoleic acid, and 5% behenic acid [18], all
of which are known to enhance wound closure
and improve healing in several wound models
[11, 12]. In addition, these fatty acids are known
to enhance permeation of the outer layers of the
skin, allowing for faster targeted delivery of
water- and oil-soluble active pharmaceutical
ingredients.
Fig. 8 Traumatic injury to the left (a) and right
(b) elbows before and to the left (a) and right
(b) elbows 11 days after application of a compounded
medicine comprising 2% mupirocin in a topical anhydrous
silicone base containing pracaxi oil; the injuries to the left
(c) and right (d) elbows were much improved
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This case series demonstrates the beneficial
effects of pracaxi oil alone when used in a
compounded silicone base, and also highlights
the ability of pracaxi oil to aid in the delivery of
topical bactericidal and collagen-modifying
drugs during wound healing and scar
formation. During this study, tranilast and
pentoxifylline, inhibitors of collagen synthesis
and wound contraction, respectively [19, 20],
were added to the compounded medicine for
one patient. As collagen is the major protein
deposited during scar formation, inhibition of
its synthesis leads to decreased scar formation.
Caffeine was also added to the compounded
medicine to increase the flow of blood to the
area and to aid in healing. In another patient,
the bactericidal agent mupirocin was
compounded with the topical anhydrous
silicone base containing pracaxi oil to prevent
infection. The ability to add these types of
active ingredients to this base may allow for the
treatment of more severe and more complex
lesions, such as burns and diabetic ulcers.
Among patients with no known underlying
comorbidities, pracaxi oil used alone or in
combination with other active ingredients in a
compounded topical anhydrous silicone base
was effective in aiding wound healing and
preventing or improving scars. Positive effects
were seen after application in several different
types of wounds including surgical, traumatic,
and burn wounds. In particular, improvements
in bilateral traumatic wounds of the elbow were
observed in one patient. The skin of the dorsal
elbow is characterized by high mobility to
enable flexion and extension of the elbow
during everyday use and is an area known to
be particularly difficult to treat [21].
Compounded topical anhydrous silicone base
containing pracaxi oil was also effective in
treating two pediatric patients: one with severe
burns on the face and one with extensive diaper
rash. These findings were in agreement with
those from a randomized, double-blind,
placebo-controlled pilot trial of a compounded
topical anhydrous silicone base containing
pracaxi oil in 11 adult volunteers with existing
surgical, traumatic, or acne-related scarring.
Patients treated with a compounded topical
anhydrous silicone base containing pracaxi oil
had a greater mean percent improvement from
baseline in scar length, scar color, pigment
intensity, contour analysis, and texture or
smoothness after 8 weeks of treatment when
compared with patients treated with placebo
(standard moisturizer) [22]. Together with the
case series described here, these results suggest
that the addition of pracaxi oil to a
compounded topical anhydrous silicone base
leads to qualitative and quantitative
improvements in wound and scar attributes.
Overall satisfaction with this compounded
base was high among all patients. During the
study, no patients reported any adverse effects
after application of compounded base
containing pracaxi oil, demonstrating that this
topical therapy is well tolerated in adults and
children.
While the results of this case series
demonstrate an improvement in wound and
scar attributes following application of a
compounded topical anhydrous silicone base
containing pracaxi oil, the study was not
without limitations. This study was conducted
in a small group of patients with varying types
and degrees of wounds and scars. Patients in
this study applied the compounded medication
as directed by their healthcare provider, and
these recommendations ranged in both the
number of daily applications as well as the
duration of application. In addition, as this
study was retrospective in nature and not
placebo- or comparator-controlled, the data
presented here should be interpreted
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cautiously. Larger, prospective, placebo-
controlled studies examining the use of the
anhydrous silicone base containing pracaxi oil
may confirm the overall effectiveness and safety
of this compound in the treatment of wounds
and scars.
CONCLUSION
This case series demonstrates that application of
a compounded anhydrous silicone base
containing fatty acids from pracaxi oil, either
alone or with the addition of other active
ingredients, is likely to improve wound and scar
attributes in pediatric and adult patients. This
study provides the groundwork for future clinical
trials investigating the use of compounded
anhydrous silicone bases containing pracaxi oil
and highlights the utility of compounding in the
treatment of wounds and scars.
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